Thienopyranecarboxamide derivatives

A method for the treatment of a patient suffering from cardiac arrhythmia, the method comprising administering an effective amount of a compound represented by the general formula I

• wherein
• R is chosen from the group consisting of an aryl, cycloalkyl, and lower polyhaloalkyl group,
• R1 is chosen from the group consisting of lower alkyl, lower alkoxy, lower polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy group, each of R2 and R3 being independently chosen from the group consisting of a hydrogen, halogen, lower alkoxy, and lower polyfluoroalkoxy group, and
• n is 0, 1 or 2,
• or a piperazine-N-oxide thereof or a pharmaceutically acceptable salt of any of the foregoing to a patient in need of such treatment.

The method according to claim or/wherein the compound represented by the general formula I is selected from the group consisting of

• N-{3-[4-(5-chloro-2-methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxamide,
• N-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxamide,
• 5-cyclohexyl-N-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-7H-thieno[3,2-b]pyran-3-carboxamide,
• N-{3-[4-(2-methoxyphenyl)-1-piperazinyl]propyl}-7-oxo-5-trifluoromethyl-7H-thieno[3,2-b]pyran-3-carboxamide,
• 7-oxo-5-phenyl-N-{3-[4-[2-(2,2,2-trifluoroethoxy)phenyl]-1-piperazinyl]propyl}-7H-thieno[3,2-b]pyran-3-carboxamide,
• N-{3-[4-[2-methoxy-5-(2,2,2-trifluoroethoxy)phenyl]-1-piperazinyl]propyl}-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxamide, and
• N-{3-[4-[4-fluoro-2-(2,2,2-trifluoroethoxy)phenyl]-1-piperazinyl]propyl}-7-oxo-5-phenyl-7H-thieno[3,2-b]pyran-3-carboxamide.

A method for the treatment of a patient suffering from erectile dysfunction, the method comprising administering an effective amount of a compound represented by the general formula I

• wherein
• R is chosen from the group consisting of an aryl, cycloalkyl, and lower polyhaloalkyl group,
• R1 is chosen from the group consisting of lower alkyl, lower alkoxy, lower polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy group, each of R2 and R3 being independently chosen from the group consisting of a hydrogen, halogen, lower alkoxy, and lower polyfluoroalkoxy group, and
• n is 0, 1 or 2,
• or a piperazine-N-oxide thereof or a pharmaceutically acceptable salt of any of the foregoing to a patient in need of such treatment.

A method for the treatment of a patient suffering from sexual dysfunction, the method comprising administering an effective amount of a compound represented by the general formula I

• wherein
• R is chosen from the group consisting of an aryl, cycloalkyl, and lower polyhaloalkyl group,
• R1 is chosen from the group consisting of lower alkyl, lower alkoxy, lower polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy group, each of R2 and R3 being independently chosen from the group consisting of a hydrogen, halogen, lower alkoxy, and lower polyfluoroalkoxy group, and
• n is 0, 1 or 2,
• or a piperazine-N-oxide thereof or a pharmaceutically acceptable salt of any of the foregoing to a patient in need of such treatment.

A method for inhibiting cholesterol synthesis in a patient, the method comprising administering an effective amount of a compound represented by the general formula

• wherein
• R is chosen from the group consisting of an aryl, cycloalkyl, and lower polyhaloalkyl group,
• R1 is chosen from the group consisting of lower alkyl, lower alkoxy, lower polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy group, each of R2 and R3 being independently chosen from the group consisting of a hydrogen, halogen, lower alkoxy, and lower polyfluoroalkoxy group, and
• n is 0, 1 or 2,
• or a piperazine-N-oxide thereof or a pharmaceutically acceptable salt of any of the foregoing to a patient in need of such treatment.

A method for reducing sympathetically mediated pain in a patient, the method comprising administering an effective amount of a compound represented by the general formula I

• wherein
• R is chosen from the group consisting of an aryl, cycloalkyl, and lower polyhaloalkyl group,
• R1 is chosen from the group consisting of lower alkyl, lower alkoxy, lower polyfluoroalkoxy, hydroxy and trifluoromethanesulfonyloxy group, each of R2 and R3 being independently chosen from the group consisting of a hydrogen, halogen, lower alkoxy, and lower polyfluoroalkoxy group, and
• n is 0, 1 or 2,
• or a piperazine-N-oxide thereof or a pharmaceutically acceptable salt of any of the foregoing to a patient in need of such treatment.